aWomen's Global Health Imperative, RTI International, Berkeley, CA;
bWits Reproductive Health and HIV Institute, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa;
cFHI360, Durham, NC; and
dDepartment of Global Health, University of Washington, Seattle, WA.
Correspondence to: Elizabeth T. Montgomery, Women's Global Health Imperative, RTI International, Berkeley, CA (e-mail: [email protected]).
The CHARISMA study was funded by the United States Agency for International Development through a cooperative agreement (AID-OAA-A-14-00012). This work was made possible by the generous support of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the American people through the United States Agency for International Development (USAID). The contents are the responsibility of the CHARISMA project and do not necessarily reflect the views of USAID, PEPFAR, or the United States Government. CHARISMA is led by RTI International with core partners FHI 360, Wits RHI, and the University of Washington.
The authors have no conflicts of interest to disclose.
Ethics approval for human studies: The study was approved by the Human Research Ethics Committee at the University of Witwatersrand and overseen by the IRB at RTI International. Consent to participate: All study participants provided written informed consent to participate in the study through a consent process approved by local ethical review committees in all research settings. Consent for publication: All participants were informed that any publication of this study will not use their name or identify them personally.
